Developing Natural Killer Cell Therapies for Hematologic Malignancies and Solid Tumors

Video

The chief executive and medical officers of Cytovia Therapeutics discussed their natural killer cell therapy technology.

“We seek to bring the power of NK cells to fight tumors in 2 ways. First, we intend to activate the already existing natural killer cells in patients by strongly engaging them to focus on tumor targets. Secondly, we will provide a readily available source of non-exhausted NK cells and the potential to repeat dosing as needed. We look to develop these approaches in tandem and in combination.”

Natural killer (NK) cells are quickly making the move from a budding area of research to a promising class of treatments in oncologic indications. As their usage grows, so too does the emergence of companies that focus on NK cells, such as Cytovia Therapeutics.

The company is focused on targeting GPC3 solid tumors and CD38 hematologic malignancies and is exploring other targets including EGFR. They are developing 2 classes of therapies, namely chimeric antigen receptor (CAR) modified NK cells and multi-specific NK engagers. Target investigational new drug filing dates range from the first quarter of 2022 to the second hald of 2022.

GeneTherapyLive spoke with Daniel Teper, PharmD, MBA, cofounder and chief executive officer, and Stanley R. Frankel, MD, chief medical officer, Cytovia Therapeutics, to learn more about their NK cell technology and its potential in both hematologic malignancies and solid tumors. They also discussed the importance of being able to manufacture scalable and modulatory products.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Related Content
© 2025 MJH Life Sciences

All rights reserved.